
## Naveen Yarlagadda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3694559/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. OncoTargets and Therapy, 2018, Volume 11, 7095-7107.	2.0	187
2	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer Journal, 2020, 10, 70.	6.2	27
3	High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: A Contemporary Experience. Urology, 2014, 83, 1129-1134.	1.0	24
4	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances, 2022, 6, 808-817.	5.2	14
5	Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. , 2020, 24, .		8
6	Hemophagocytic lymphohistiocytosis in adults. Baylor University Medical Center Proceedings, 2020, 33, 326-330.	0.5	5
7	Persistent bone marrow minimal residual disease as a "highâ€risk―disease feature in multiple myeloma. American Journal of Hematology, 2021, 96, E341-E344.	4.1	4
8	Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 911-915.	4.9	3
9	Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. Leukemia Research, 2021, 110, 106714.	0.8	2
10	The Mutational Landscape of Primary Plasma Cell Leukemia. Blood, 2018, 132, 114-114.	1.4	2
11	Clinical characteristics of testicular extramedullary involvement in multiple myeloma. American Journal of Hematology, 2021, 96, E77-E81.	4.1	1
12	1593. Recurrence of <i>Clostridium difficile</i> Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis. Open Forum Infectious Diseases, 2018, 5, S498-S499.	0.9	0
13	Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma. Baylor University Medical Center Proceedings, 2020, 33, 59-61.	0.5	0
14	Characteristics, associations, and outcomes of hemophagocytic lymphohistiocytosis: Retrospective data over a period of 13 years from a university hospital Journal of Clinical Oncology, 2018, 36, e19563.	1.6	0
15	Survey of Compliance to Infection Control Measures and Its Impact on Healthcare of Patients in a Hematopoietic Stem Cell Transplant Unit. Blood, 2018, 132, 5825-5825.	1.4	0
16	Treatment Strategies and Outcomes for Patients with Peripheral T-Cell Lymphoma and Its Subtypes. Blood, 2020, 136, 36-37.	1.4	0
17	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American Journal of Hematology, 2022, 97, .	4.1	0